Laparoscopic surgery with chemotherapy for advanced gastric cancer
Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Gastric Cancer After Laparoscopic Gastrectomy With D2 Lymphadenectomy: A Phase III Multicenter Prospective Randomized Controlled Clinical Trial
This study is testing if adding a special heated chemotherapy treatment during surgery can help people with advanced stomach cancer live longer and avoid cancer spreading in their abdomen.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 616 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | The Affiliated Hospital of Qingdao University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Qingdao, Shandong) |
| Trial ID | NCT05871099 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) combined with laparoscopic gastrectomy and D2 lymphadenectomy in patients with locally advanced gastric cancer. Participants will be randomly assigned to either receive HIPEC along with systemic chemotherapy or systemic chemotherapy alone after their surgical procedure. The primary aim is to determine if the addition of HIPEC improves the 5-year overall survival rate and reduces the incidence of peritoneal metastases. The study focuses on patients who have not undergone prior chemotherapy or radiotherapy.
Who should consider this trial
Good fit: Ideal candidates are newly diagnosed patients aged 18-80 with advanced gastric adenocarcinoma who are eligible for laparoscopic radical gastrectomy.
Not a fit: Patients with distant metastasis or those who have previously received chemotherapy or radiotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve survival rates and reduce cancer recurrence in patients with advanced gastric cancer.
How similar studies have performed: Previous studies have shown promising results with HIPEC in various cancers, suggesting potential success for this approach in gastric cancer as well.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: (1) Newly treated patients who did not receive chemotherapy, radiotherapy or other antitumor therapy before the start of the clinical trial;(2) Aged 18-80 years;(3) male or non-pregnant or lactating female;(4) Gastric adenocarcinoma was pathologically confirmed, and laparoscopic (robotic) radical gastrectomy was planned;(5) Patients with T stage T3 or above, no distant metastasis, and feasible criteria for laparoscopic D2 radical resection (AJCC Eighth edition);(6) The estimated survival time is more than 6 months;(7) History of nonabdominal surgery (except laparoscopic cholecystectomy);(8) The bone marrow reserve function was good, and the blood routine met the following conditions: white blood cell count ≥3.5×109/L, neutrophil ≥1.5×109/L, platelet count ≥100×109/L, hemoglobin ≥90g/L;(9) Organ function was good, and biochemical examination met the following conditions: ALT≤2.5× upper limit of normal value (ULN), AST≤2.5×ULN, serum total bilirubin ≤1.5×ULN, serum creatinine ≤1.5×ULN;(10) Functional status: 0-1 (ECOG);(11) Preoperative ASA grade I-III;(12) Voluntarily sign the informed consent. Exclusion Criteria: (1) Lymph node BulkyN2 status was diagnosed by abdominal CT/MRI, that is, at least one lymph node meridian ≥3cm or three consecutive lymph nodes, each meridian ≥1.5cm;(2) pregnant or lactating women;(3) Other malignant tumors within 5 years;(4) Preoperative temperature ≥38℃ or complicated with infectious diseases requiring systematic treatment;(5) serious mental illness;(6) Severe respiratory diseases, FEV1\< 50%;(7) Severe liver and kidney dysfunction, liver enzyme elevation more than 2 times the normal value;(8) History of unstable angina pectoris or myocardial infarction within 6 months;(9) History of cerebral infarction or cerebral hemorrhage within 6 months, except old infarct;(10) Systemic glucocorticoid therapy within 1 month;(11) Patients with gastric cancer complications (bleeding, perforation, obstruction) requiring emergency surgery;(12) The patient has participated in or is currently participating in other clinical studies (within 6 months);(13) Laparoscopic exploration, biopsy and cytology confirmed intraperitoneal implantation and metastasis.
Where this trial is running
Qingdao, Shandong
- The Affiliated Hospital of Qingdao University — Qingdao, Shandong, China (Recruiting)
Study contacts
- Study coordinator: Yanbing Zhou, MD
- Email: zhouyanbing@qduhospital.cn
- Phone: 86532-82911324
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.